Incyte | INCY - Operating Expenses

Stock Price
94.65
Daily Change
-0.82 -0.86%
Monthly
2.62%
Yearly
59.99%
Q2 Forecast
92.62

Incyte reported $1.12B in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 266.6M 23.72M Dec/2025
Agenus USD 19.81M 293.94M Dec/2025
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amgen USD 5.9B 773M Dec/2025
BioCryst Pharmaceuticals USD 146.17M 534.06M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Exelixis USD 362.75M 21.35M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
Ionis Pharmaceuticals USD 418M 101.1M Dec/2025
MacroGenics USD 53.32M 13.68M Dec/2025
Merck USD 10.16B 558M Dec/2025
Moderna USD 1.54B 259M Dec/2025
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Novartis USD 9.8B 61M Dec/2025
Novartis USD 9.8B 23M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025